Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
| العنوان: | Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study |
|---|---|
| المؤلفون: | Carmona-Bayonas, Alberto, Jiménez-Fonseca, Paula, Lamarca, Ángela, Barriuso, Jorge, Castaño, Ángel, Benavent, Marta, Alonso, Vicente, Riesco-Martínez, María del Carmen, Alonso-Gordoa, Teresa, Custodio, Ana, Sánchez Cánovas, Manuel, Hernando Cubero, Jorge, López, Carlos, Lacasta, Adelaida, Fernández Montes, Ana, Marazuela, Mónica, Crespo, Guillermo, Escudero, Pilar, Diaz, José Ángel, Feliciangeli, Eduardo, Gallego, Javier, Llanos, Marta, Segura, Ángel, Vilardell, Felip, Percovich, Juan Carlos, Grande, Enrique, Capdevila Castillón, Jaume, Valle, Juan W., García-Carbonero, Rocío, Universitat Autònoma de Barcelona |
| المساهمون: | LEO Pharma, Ipsen, Pfizer, Roche, Amgen, Merck & Co, Merck Sharp & Dohme, AstraZeneca, Sanofi, Bayer, Eisai, Celgene, Novartis, Advanced Accelerator Applications, Bristol-Myers Squibb, UAM. Departamento de Medicina, Novartis Farmaceútica |
| المصدر: | JOURNAL OF CLINICAL ONCOLOGY r-FISABIO. Repositorio Institucional de Producción Científica instname Digital.CSIC. Repositorio Institucional del CSIC Biblos-e Archivo. Repositorio Institucional de la UAM Carmona-bayonas, A, Jiménez-fonseca, P, Lamarca, Á, Barriuso, J, Castaño, Á, Benavent, M, Alonso, V, Riesco-martínez, M D C, Alonso-gordoa, T, Custodio, A, Sánchez Cánovas, M, Hernando Cubero, J, López, C, Lacasta, A, Fernández Montes, A, Marazuela, M, Crespo, G, Escudero, P, Diaz, J Á, Feliciangeli, E, Gallego, J, Llanos, M, Segura, Á, Vilardell, F, Percovich, J C, Grande, E, Capdevila, J, Valle, J W & García-carbonero, R 2019, ' Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study ', Journal of Clinical Oncology, pp. JCO.19.00980 . https://doi.org/10.1200/JCO.19.00980Test Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) Journal of Clinical Oncology Repisalud Instituto de Salud Carlos III (ISCIII) r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe |
| بيانات النشر: | AMER SOC CLINICAL ONCOLOGY, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Cancer Research, Octreotide, Neuroendocrine tumors, Lanreotide, THERAPY, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, PROGNOSTIC-FACTORS, EVEROLIMUS, Gastrointestinal Cancer, prognostic model, Manchester Cancer Research Centre, ORIGINAL REPORTS, somatostatin analogs, Progression-Free Survival, Neuroendocrine Tumors, 030220 oncology & carcinogenesis, Female, lanreotide, Somatostatin, medicine.drug, Cohort study, NEOPLASMS, Adult, medicine.medical_specialty, Adolescent, Medicina, SUNITINIB, nomogram, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Progression-free survival, Survival analysis, Retrospective Studies, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Retrospective cohort study, Nomogram, medicine.disease, Survival Analysis, Hormones, MODEL, 030104 developmental biology, chemistry, REGISTRY, business, octreotide |
| الوصف: | [Purpose] Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients. [Patient and methods] We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP primary, Ki-67 of 20% or less, and first-line SSA monotherapy for advanced disease. An accelerated failure time model was developed to predict PFS, which was represented as a nomogram and an online calculator. The nomogram was externally validated in an independent series of consecutive eligible patients (The Christie NHS Foundation Trust, Manchester, United Kingdom). [Results] We recruited 535 patients (R-GETNE, n = 438; Manchester, n = 97). Median PFS and overall survival in the derivation cohort were 28.7 (95% CI, 23.8 to 31.1) and 85.9 months (95% CI, 71.5 to 96.7 months), respectively. Nine covariates significantly associated with PFS were primary tumor location, Ki-67 percentage, neutrophil-to-lymphocyte ratio, alkaline phosphatase, extent of liver involvement, presence of bone and peritoneal metastases, documented progression status, and the presence of symptoms when initiating SSA. The GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) model demonstrated suitable calibration, as well as fair discrimination ability with a C-index value of 0.714 (95% CI, 0.680 to 0.747) and 0.732 (95% CI, 0.658 to 0.806) in the derivation and validation series, respectively. [Conclusion] The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according to their estimated PFS. This nomogram may be useful when stratifying patients with neuroendocrine tumors in future trials. Furthermore, it could be a valuable tool for making treatment decisions in daily clinical practice. |
| وصف الملف: | application/pdf |
| تدمد: | 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abca4a41dc814f6e3652d2060787a26Test https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7071Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8abca4a41dc814f6e3652d2060787a26 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....8abca4a41dc814f6e3652d2060787a26 831 3 unknown 830.687927246094 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8abca4a41dc814f6e3652d2060787a26&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Carmona-Bayonas%2C+Alberto%22">Carmona-Bayonas, Alberto</searchLink><br /><searchLink fieldCode="AR" term="%22Jiménez-Fonseca%2C+Paula%22">Jiménez-Fonseca, Paula</searchLink><br /><searchLink fieldCode="AR" term="%22Lamarca%2C+Ángela%22">Lamarca, Ángela</searchLink><br /><searchLink fieldCode="AR" term="%22Barriuso%2C+Jorge%22">Barriuso, Jorge</searchLink><br /><searchLink fieldCode="AR" term="%22Castaño%2C+Ángel%22">Castaño, Ángel</searchLink><br /><searchLink fieldCode="AR" term="%22Benavent%2C+Marta%22">Benavent, Marta</searchLink><br /><searchLink fieldCode="AR" term="%22Alonso%2C+Vicente%22">Alonso, Vicente</searchLink><br /><searchLink fieldCode="AR" term="%22Riesco-Martínez%2C+María+del+Carmen%22">Riesco-Martínez, María del Carmen</searchLink><br /><searchLink fieldCode="AR" term="%22Alonso-Gordoa%2C+Teresa%22">Alonso-Gordoa, Teresa</searchLink><br /><searchLink fieldCode="AR" term="%22Custodio%2C+Ana%22">Custodio, Ana</searchLink><br /><searchLink fieldCode="AR" term="%22Sánchez+Cánovas%2C+Manuel%22">Sánchez Cánovas, Manuel</searchLink><br /><searchLink fieldCode="AR" term="%22Hernando+Cubero%2C+Jorge%22">Hernando Cubero, Jorge</searchLink><br /><searchLink fieldCode="AR" term="%22López%2C+Carlos%22">López, Carlos</searchLink><br /><searchLink fieldCode="AR" term="%22Lacasta%2C+Adelaida%22">Lacasta, Adelaida</searchLink><br /><searchLink fieldCode="AR" term="%22Fernández+Montes%2C+Ana%22">Fernández Montes, Ana</searchLink><br /><searchLink fieldCode="AR" term="%22Marazuela%2C+Mónica%22">Marazuela, Mónica</searchLink><br /><searchLink fieldCode="AR" term="%22Crespo%2C+Guillermo%22">Crespo, Guillermo</searchLink><br /><searchLink fieldCode="AR" term="%22Escudero%2C+Pilar%22">Escudero, Pilar</searchLink><br /><searchLink fieldCode="AR" term="%22Diaz%2C+José+Ángel%22">Diaz, José Ángel</searchLink><br /><searchLink fieldCode="AR" term="%22Feliciangeli%2C+Eduardo%22">Feliciangeli, Eduardo</searchLink><br /><searchLink fieldCode="AR" term="%22Gallego%2C+Javier%22">Gallego, Javier</searchLink><br /><searchLink fieldCode="AR" term="%22Llanos%2C+Marta%22">Llanos, Marta</searchLink><br /><searchLink fieldCode="AR" term="%22Segura%2C+Ángel%22">Segura, Ángel</searchLink><br /><searchLink fieldCode="AR" term="%22Vilardell%2C+Felip%22">Vilardell, Felip</searchLink><br /><searchLink fieldCode="AR" term="%22Percovich%2C+Juan+Carlos%22">Percovich, Juan Carlos</searchLink><br /><searchLink fieldCode="AR" term="%22Grande%2C+Enrique%22">Grande, Enrique</searchLink><br /><searchLink fieldCode="AR" term="%22Capdevila+Castillón%2C+Jaume%22">Capdevila Castillón, Jaume</searchLink><br /><searchLink fieldCode="AR" term="%22Valle%2C+Juan+W%2E%22">Valle, Juan W.</searchLink><br /><searchLink fieldCode="AR" term="%22García-Carbonero%2C+Rocío%22">García-Carbonero, Rocío</searchLink><br /><searchLink fieldCode="AR" term="%22Universitat+Autònoma+de+Barcelona%22">Universitat Autònoma de Barcelona</searchLink> ) Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => LEO Pharma<br />Ipsen<br />Pfizer<br />Roche<br />Amgen<br />Merck & Co<br />Merck Sharp & Dohme<br />AstraZeneca<br />Sanofi<br />Bayer<br />Eisai<br />Celgene<br />Novartis<br />Advanced Accelerator Applications<br />Bristol-Myers Squibb<br />UAM. Departamento de Medicina<br />Novartis Farmaceútica ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => JOURNAL OF CLINICAL ONCOLOGY<br />r-FISABIO. Repositorio Institucional de Producción Científica<br />instname<br />Digital.CSIC. Repositorio Institucional del CSIC<br />Biblos-e Archivo. Repositorio Institucional de la UAM<br />Carmona-bayonas, A, Jiménez-fonseca, P, Lamarca, Á, Barriuso, J, Castaño, Á, Benavent, M, Alonso, V, Riesco-martínez, M D C, Alonso-gordoa, T, Custodio, A, Sánchez Cánovas, M, Hernando Cubero, J, López, C, Lacasta, A, Fernández Montes, A, Marazuela, M, Crespo, G, Escudero, P, Diaz, J Á, Feliciangeli, E, Gallego, J, Llanos, M, Segura, Á, Vilardell, F, Percovich, J C, Grande, E, Capdevila, J, Valle, J W & García-carbonero, R 2019, ' Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study ', Journal of Clinical Oncology, pp. JCO.19.00980 . https://doi.org/10.1200/JCO.19.00980<br />Dipòsit Digital de Documents de la UAB<br />Universitat Autònoma de Barcelona<br />r-FISABIO: Repositorio Institucional de Producción Científica<br />Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)<br />Journal of Clinical Oncology<br />Repisalud<br />Instituto de Salud Carlos III (ISCIII)<br />r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => AMER SOC CLINICAL ONCOLOGY, 2019. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%220301+basic+medicine%22">0301 basic medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+Research%22">Cancer Research</searchLink><br /><searchLink fieldCode="DE" term="%22Octreotide%22">Octreotide</searchLink><br /><searchLink fieldCode="DE" term="%22Neuroendocrine+tumors%22">Neuroendocrine tumors</searchLink><br /><searchLink fieldCode="DE" term="%22Lanreotide%22">Lanreotide</searchLink><br /><searchLink fieldCode="DE" term="%22THERAPY%22">THERAPY</searchLink><br /><searchLink fieldCode="DE" term="%22Cohort+Studies%22">Cohort Studies</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%2Echemical%5Fcompound%22">chemistry.chemical_compound</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22PROGNOSTIC-FACTORS%22">PROGNOSTIC-FACTORS</searchLink><br /><searchLink fieldCode="DE" term="%22EVEROLIMUS%22">EVEROLIMUS</searchLink><br /><searchLink fieldCode="DE" term="%22Gastrointestinal+Cancer%22">Gastrointestinal Cancer</searchLink><br /><searchLink fieldCode="DE" term="%22prognostic+model%22">prognostic model</searchLink><br /><searchLink fieldCode="DE" term="%22Manchester+Cancer+Research+Centre%22">Manchester Cancer Research Centre</searchLink><br /><searchLink fieldCode="DE" term="%22ORIGINAL+REPORTS%22">ORIGINAL REPORTS</searchLink><br /><searchLink fieldCode="DE" term="%22somatostatin+analogs%22">somatostatin analogs</searchLink><br /><searchLink fieldCode="DE" term="%22Progression-Free+Survival%22">Progression-Free Survival</searchLink><br /><searchLink fieldCode="DE" term="%22Neuroendocrine+Tumors%22">Neuroendocrine Tumors</searchLink><br /><searchLink fieldCode="DE" term="%22030220+oncology+%26+carcinogenesis%22">030220 oncology & carcinogenesis</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22lanreotide%22">lanreotide</searchLink><br /><searchLink fieldCode="DE" term="%22Somatostatin%22">Somatostatin</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink><br /><searchLink fieldCode="DE" term="%22Cohort+study%22">Cohort study</searchLink><br /><searchLink fieldCode="DE" term="%22NEOPLASMS%22">NEOPLASMS</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Adolescent%22">Adolescent</searchLink><br /><searchLink fieldCode="DE" term="%22Medicina%22">Medicina</searchLink><br /><searchLink fieldCode="DE" term="%22SUNITINIB%22">SUNITINIB</searchLink><br /><searchLink fieldCode="DE" term="%22nomogram%22">nomogram</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Young+Adult%22">Young Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Progression-free+survival%22">Progression-free survival</searchLink><br /><searchLink fieldCode="DE" term="%22Survival+analysis%22">Survival analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+Studies%22">Retrospective Studies</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22ResearchInstitutes%5FNetworks%5FBeacons%2Fmcrc%22">ResearchInstitutes_Networks_Beacons/mcrc</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+cohort+study%22">Retrospective cohort study</searchLink><br /><searchLink fieldCode="DE" term="%22Nomogram%22">Nomogram</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Survival+Analysis%22">Survival Analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Hormones%22">Hormones</searchLink><br /><searchLink fieldCode="DE" term="%22MODEL%22">MODEL</searchLink><br /><searchLink fieldCode="DE" term="%22030104+developmental+biology%22">030104 developmental biology</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%22">chemistry</searchLink><br /><searchLink fieldCode="DE" term="%22REGISTRY%22">REGISTRY</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22octreotide%22">octreotide</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => [Purpose] Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients.<br />[Patient and methods] We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP primary, Ki-67 of 20% or less, and first-line SSA monotherapy for advanced disease. An accelerated failure time model was developed to predict PFS, which was represented as a nomogram and an online calculator. The nomogram was externally validated in an independent series of consecutive eligible patients (The Christie NHS Foundation Trust, Manchester, United Kingdom).<br />[Results] We recruited 535 patients (R-GETNE, n = 438; Manchester, n = 97). Median PFS and overall survival in the derivation cohort were 28.7 (95% CI, 23.8 to 31.1) and 85.9 months (95% CI, 71.5 to 96.7 months), respectively. Nine covariates significantly associated with PFS were primary tumor location, Ki-67 percentage, neutrophil-to-lymphocyte ratio, alkaline phosphatase, extent of liver involvement, presence of bone and peritoneal metastases, documented progression status, and the presence of symptoms when initiating SSA. The GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) model demonstrated suitable calibration, as well as fair discrimination ability with a C-index value of 0.714 (95% CI, 0.680 to 0.747) and 0.732 (95% CI, 0.658 to 0.806) in the derivation and validation series, respectively.<br />[Conclusion] The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according to their estimated PFS. This nomogram may be useful when stratifying patients with neuroendocrine tumors in future trials. Furthermore, it could be a valuable tool for making treatment decisions in daily clinical practice. ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => application/pdf ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 0732-183X ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abca4a41dc814f6e3652d2060787a26" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abca4a41dc814f6e3652d2060787a26</link><br /><link linkTarget="URL" linkTerm="https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7071" linkWindow="_blank">https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7071</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....8abca4a41dc814f6e3652d2060787a26 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => 0301 basic medicine
[Type] => general
)
[1] => Array
(
[SubjectFull] => Oncology
[Type] => general
)
[2] => Array
(
[SubjectFull] => Male
[Type] => general
)
[3] => Array
(
[SubjectFull] => Cancer Research
[Type] => general
)
[4] => Array
(
[SubjectFull] => Octreotide
[Type] => general
)
[5] => Array
(
[SubjectFull] => Neuroendocrine tumors
[Type] => general
)
[6] => Array
(
[SubjectFull] => Lanreotide
[Type] => general
)
[7] => Array
(
[SubjectFull] => THERAPY
[Type] => general
)
[8] => Array
(
[SubjectFull] => Cohort Studies
[Type] => general
)
[9] => Array
(
[SubjectFull] => chemistry.chemical_compound
[Type] => general
)
[10] => Array
(
[SubjectFull] => 0302 clinical medicine
[Type] => general
)
[11] => Array
(
[SubjectFull] => PROGNOSTIC-FACTORS
[Type] => general
)
[12] => Array
(
[SubjectFull] => EVEROLIMUS
[Type] => general
)
[13] => Array
(
[SubjectFull] => Gastrointestinal Cancer
[Type] => general
)
[14] => Array
(
[SubjectFull] => prognostic model
[Type] => general
)
[15] => Array
(
[SubjectFull] => Manchester Cancer Research Centre
[Type] => general
)
[16] => Array
(
[SubjectFull] => ORIGINAL REPORTS
[Type] => general
)
[17] => Array
(
[SubjectFull] => somatostatin analogs
[Type] => general
)
[18] => Array
(
[SubjectFull] => Progression-Free Survival
[Type] => general
)
[19] => Array
(
[SubjectFull] => Neuroendocrine Tumors
[Type] => general
)
[20] => Array
(
[SubjectFull] => 030220 oncology & carcinogenesis
[Type] => general
)
[21] => Array
(
[SubjectFull] => Female
[Type] => general
)
[22] => Array
(
[SubjectFull] => lanreotide
[Type] => general
)
[23] => Array
(
[SubjectFull] => Somatostatin
[Type] => general
)
[24] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
[25] => Array
(
[SubjectFull] => Cohort study
[Type] => general
)
[26] => Array
(
[SubjectFull] => NEOPLASMS
[Type] => general
)
[27] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[28] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[29] => Array
(
[SubjectFull] => Adolescent
[Type] => general
)
[30] => Array
(
[SubjectFull] => Medicina
[Type] => general
)
[31] => Array
(
[SubjectFull] => SUNITINIB
[Type] => general
)
[32] => Array
(
[SubjectFull] => nomogram
[Type] => general
)
[33] => Array
(
[SubjectFull] => 03 medical and health sciences
[Type] => general
)
[34] => Array
(
[SubjectFull] => Young Adult
[Type] => general
)
[35] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[36] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[37] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[38] => Array
(
[SubjectFull] => Progression-free survival
[Type] => general
)
[39] => Array
(
[SubjectFull] => Survival analysis
[Type] => general
)
[40] => Array
(
[SubjectFull] => Retrospective Studies
[Type] => general
)
[41] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[42] => Array
(
[SubjectFull] => ResearchInstitutes_Networks_Beacons/mcrc
[Type] => general
)
[43] => Array
(
[SubjectFull] => Retrospective cohort study
[Type] => general
)
[44] => Array
(
[SubjectFull] => Nomogram
[Type] => general
)
[45] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[46] => Array
(
[SubjectFull] => Survival Analysis
[Type] => general
)
[47] => Array
(
[SubjectFull] => Hormones
[Type] => general
)
[48] => Array
(
[SubjectFull] => MODEL
[Type] => general
)
[49] => Array
(
[SubjectFull] => 030104 developmental biology
[Type] => general
)
[50] => Array
(
[SubjectFull] => chemistry
[Type] => general
)
[51] => Array
(
[SubjectFull] => REGISTRY
[Type] => general
)
[52] => Array
(
[SubjectFull] => business
[Type] => general
)
[53] => Array
(
[SubjectFull] => octreotide
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Carmona-Bayonas, Alberto
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jiménez-Fonseca, Paula
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lamarca, Ángela
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Barriuso, Jorge
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Castaño, Ángel
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Benavent, Marta
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alonso, Vicente
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Riesco-Martínez, María del Carmen
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alonso-Gordoa, Teresa
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Custodio, Ana
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sánchez Cánovas, Manuel
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hernando Cubero, Jorge
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => López, Carlos
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lacasta, Adelaida
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fernández Montes, Ana
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marazuela, Mónica
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Crespo, Guillermo
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Escudero, Pilar
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Diaz, José Ángel
)
)
)
[19] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Feliciangeli, Eduardo
)
)
)
[20] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gallego, Javier
)
)
)
[21] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Llanos, Marta
)
)
)
[22] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Segura, Ángel
)
)
)
[23] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vilardell, Felip
)
)
)
[24] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Percovich, Juan Carlos
)
)
)
[25] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Grande, Enrique
)
)
)
[26] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Capdevila Castillón, Jaume
)
)
)
[27] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Valle, Juan W.
)
)
)
[28] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => García-Carbonero, Rocío
)
)
)
[29] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Universitat Autònoma de Barcelona
)
)
)
[30] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => LEO Pharma
)
)
)
[31] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ipsen
)
)
)
[32] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pfizer
)
)
)
[33] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Roche
)
)
)
[34] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Amgen
)
)
)
[35] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Merck & Co
)
)
)
[36] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Merck Sharp & Dohme
)
)
)
[37] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => AstraZeneca
)
)
)
[38] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sanofi
)
)
)
[39] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bayer
)
)
)
[40] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Eisai
)
)
)
[41] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Celgene
)
)
)
[42] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Novartis
)
)
)
[43] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Advanced Accelerator Applications
)
)
)
[44] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bristol-Myers Squibb
)
)
)
[45] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => UAM. Departamento de Medicina
)
)
)
[46] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Novartis Farmaceútica
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 0732183X
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
)
)
)
)
)
|
| IllustrationInfo |